Genfit S.A. Cash Flow Conversion Efficiency
Genfit S.A. cash flow conversion efficiency. Based on the latest financial reports, Genfit S.A. (GNFT) has a cash flow conversion efficiency ratio of -0.574x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.10 Million) by net assets ($52.47 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Genfit S.A. (2004–2024)
Cash flow conversion efficiency of Genfit S.A. from 2004 to 2024. This chart illustrates how Genfit S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Genfit S.A. for real-time trading data and today's change.
Genfit S.A. Cash Flow Conversion Ratio Explained
Genfit S.A. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Genfit S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genfit S.A. ranked by their cash flow conversion efficiency. Also see GNFT market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Soltec Power Holdings S.A
MC:SOL
|
0.089x |
|
Gateway Distriparks Limited
NSE:GATEWAY
|
0.079x |
|
Xpro India Limited
NSE:XPROINDIA
|
-0.003x |
|
Lantronix Inc
NASDAQ:LTRX
|
0.016x |
|
Guangdong Tengen Industrial Group C
SHE:003003
|
0.025x |
|
Patel Engineering Limited
NSE:PATELENG
|
0.086x |
|
Darfon Electronics Corp
TW:8163
|
-0.023x |
|
Pix Transmissions Limited
NSE:PIXTRANS
|
0.128x |
Annual Cash Flow Conversion Efficiency for Genfit S.A. (2004–2024)
The table below shows the annual cash flow conversion efficiency of Genfit S.A. from 2004 to 2024. Review Genfit S.A. free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $69.22 Million | $15.55 Million | 0.225x | +127.54% |
| 2023-12-31 | $67.95 Million | $-55.43 Million | -0.816x | -6.15% |
| 2022-12-31 | $94.53 Million | $-72.64 Million | -0.768x | -191.60% |
| 2021-12-31 | $119.10 Million | $99.92 Million | 0.839x | -85.93% |
| 2020-12-31 | $-16.16 Million | $-96.37 Million | 5.963x | +1151.31% |
| 2019-12-31 | $84.06 Million | $-47.68 Million | -0.567x | +78.82% |
| 2018-12-31 | $20.94 Million | $-56.08 Million | -2.678x | -459.93% |
| 2017-12-31 | $104.23 Million | $-49.86 Million | -0.478x | -150.88% |
| 2016-12-31 | $142.80 Million | $-27.23 Million | -0.191x | +28.95% |
| 2015-12-31 | $55.42 Million | $-14.87 Million | -0.268x | -21.99% |
| 2014-12-31 | $70.43 Million | $-15.49 Million | -0.220x | +66.27% |
| 2013-12-31 | $14.09 Million | $-9.19 Million | -0.652x | +43.31% |
| 2012-12-31 | $6.83 Million | $-7.86 Million | -1.150x | +27.92% |
| 2011-12-31 | $4.46 Million | $-7.11 Million | -1.596x | -148.23% |
| 2010-12-31 | $8.39 Million | $-5.39 Million | -0.643x | -4415.44% |
| 2009-12-31 | $15.52 Million | $-221.00K | -0.014x | +93.83% |
| 2008-12-31 | $22.38 Million | $-5.16 Million | -0.231x | -21.55% |
| 2007-12-31 | $25.37 Million | $-4.81 Million | -0.190x | -202.28% |
| 2006-12-31 | $27.77 Million | $-1.74 Million | -0.063x | -150.16% |
| 2005-12-31 | $13.39 Million | $1.68 Million | 0.125x | -54.99% |
| 2004-12-31 | $14.00 Million | $3.89 Million | 0.278x | -- |
About Genfit S.A.
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fi… Read more